Preventive therapy for breast cancer: a consensus statement (Q37858249)

24 August 2017

1 reference

title

Preventive therapy for breast cancer: a consensus statement (English)

1 reference

24 August 2017

1 reference

9

1 reference

24 August 2017

10

Gunter von Minckwitz

0 references

Jack Cuzick

1

object named as

Jack Cuzick

1 reference

24 August 2017

Andrea DeCensi

2

1 reference

24 August 2017

Banu Arun

3

1 reference

24 August 2017

Powel H Brown

4

1 reference

24 August 2017

Monica Castiglione

5

1 reference

24 August 2017

Barbara Dunn

6

1 reference

24 August 2017

John F Forbes

7

1 reference

24 August 2017

Agnes Glaus

8

1 reference

24 August 2017

Victor Vogel

11

1 reference

24 August 2017

Heinz Zwierzina

12

1 reference

24 August 2017

1 May 2011

1 reference

Lancet Oncology Commission

24 August 2017

1 reference

24 August 2017

12

1 reference

24 August 2017

5

1 reference

24 August 2017

496-503

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

24 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Global trends in breast cancer incidence and mortality 1973-1997.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Genetic predisposition to breast cancer: past, present, and future

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Genome-wide association study identifies novel breast cancer susceptibility loci

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Genome-wide association study identifies five new breast cancer susceptibility loci

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Mammographic Density and the Risk and Detection of Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Breast-tissue sampling for risk assessment and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Long-term results of tamoxifen prophylaxis for breast cancer--96-month follow-up of the randomized IBIS-I trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Lasofoxifene in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Aromatase inhibitors for breast cancer prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Fifteen-year results of a randomized phase III trial of fenretinide to prevent second breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Use of bisphosphonates and risk of postmenopausal breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Oral bisphosphonate use and breast cancer incidence in postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Long-term metformin use is associated with decreased risk of breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

The effects of tibolone in older postmenopausal women

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Statins and risk of cancer: a systematic review and metaanalysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Use of statins and breast cancer: a meta-analysis of seven randomized clinical trials and nine observational studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Statins and cancer risk: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Association between NSAIDs use and breast cancer risk: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Overview of the main outcomes in breast-cancer prevention trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

HRT opposed to low-dose tamoxifen (HOT study): rationale and design.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Chemoprevention of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Bisphosphonates: mechanisms of action

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

A pharmacological assessment of the mammalian osteoclast vacuolar H(+)-ATPase

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Endocrine therapy plus zoledronic acid in premenopausal breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Meta-analysis of clodronate and breast cancer survival

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Metformin extends life span of HER-2/neu transgenic mice and in combination with melatonin inhibits growth of transplantable tumors in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

A risk-benefit assessment of metformin in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Is it time to test metformin in breast cancer clinical trials?

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Metformin in breast cancer: time for action

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Statin use and breast cancer: prospective results from the Women's Health Initiative.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Serum lipids, lipid-lowering drugs, and the risk of breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Statin use and cancer risk in the General Practice Research Database

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Breast cancer and hormone-replacement therapy in the Million Women Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Innovative agents in cancer prevention.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Projecting individualized probabilities of developing breast cancer for white females who are being examined annually

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

A breast cancer prediction model incorporating familial and personal risk factors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Ki67: a time-varying biomarker of risk of breast cancer in atypical hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-alpha and Ki-67 expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Development of a high-throughput screening-amenable assay for human poly(ADP-ribose) polymerase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

Metformin and reduced risk of cancer in diabetic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2811%2970030-4

7 January 2021

10.1016/S1470-2045(11)70030-4

Identifiers

DOI

1 reference

24 August 2017

1 reference